Does Kanna Get You High? What the Research Says About Its Effects
If you have been scrolling through wellness feeds lately, you have probably stumbled across kanna and wondered what exactly it does. The word "high" gets thrown around a lot in these conversations, which makes sense given that kanna is sometimes nicknamed "nature's MDMA." But that label creates more confusion than clarity.
Does kanna get you high in the traditional sense? Is it intoxicating? Is it safe?
The answers are more nuanced than a simple yes or no, and they matter if you are serious about making informed choices around what you put in your body.
At Kamello, kanna is one of two core botanicals behind every can, chosen specifically because of what the science actually shows rather than what the hype suggests. Understanding the real story behind this plant is central to understanding what Kamello is built on.
This article breaks down what kanna is, what the research says about how it affects the brain and body, and why the "high" framing might be missing the point entirely. By the end, you will have a much clearer picture of this ancient South African botanical and why modern wellness culture is paying close attention.
The Ancient Botanical Taking the Wellness World by Storm
A 300-Year-Old Secret Hidden in a South African Succulent
Kanna, botanically known as Sceletium tortuosum, is a succulent plant native to South Africa. Indigenous communities, particularly the Khoikhoi and San peoples, have used it for centuries as a calming, stress-reducing herb.
The record of its use stretches back further than most people realize. Jan van Riebeeck's journals from 1662 contain some of the earliest European documentation of indigenous kanna use, describing it as a substance traded and consumed for its mood-altering properties. That is over 360 years of human use before a single clinical trial was ever conducted.
Traditional applications ranged from chewing fermented plant material during long hunts to using it as a social aid during communal gatherings. The plant contains a class of alkaloids, most notably mesembrine and mesembrenone, which are believed to drive its psychoactive properties. These alkaloids interact with serotonin transporters in the brain, a mechanism that has drawn serious scientific attention in recent years.
Calm, Clarity, or Something Else? Where Kanna Really Lands
Not all psychoactive substances are created equal. Alcohol, cannabis, MDMA, and psilocybin all alter consciousness in dramatically different ways. Kanna sits in a much gentler category.
Its primary mechanism involves serotonin reuptake inhibition, similar in principle to certain antidepressants, along with phosphodiesterase 4 (PDE4) inhibition, which plays a role in cognitive function and mood.
Kanna does not produce hallucinations or dissociation. Most users report calm alertness, reduced social anxiety, and a lift in mood rather than anything resembling intoxication. At Kamello, this is why kanna is central to the formulation.
What Happens in Your Brain When You Take Kanna
The Clinical Studies That Are Turning Heads
Clinical research on kanna is still developing, but the existing studies are encouraging.
A 2013 randomized controlled trial published in Neuropsychopharmacology found that a standardized Sceletium tortuosum extract (Zembrin) significantly reduced anxiety responses in the amygdala, the brain region most associated with fear and stress. Participants showed measurable changes in neural activity without sedation or cognitive impairment.
Notably, researchers have also evaluated kanna as a potential antidepressant, with a 2021 review in Frontiers in Pharmacology assessing its clinical potential for depression treatment. The review found solid support for kanna's mood-regulating properties while stopping well short of overstating its effects.
This kind of measured scientific validation is what distinguishes a credible plant medicine from wellness marketing noise.
Two Pathways, One Surprisingly Balanced Effect
The alkaloids in kanna work through two primary pathways. The first is serotonin transporter (SERT) inhibition, which increases the availability of serotonin in synaptic gaps. This is the mechanism associated with mood elevation, reduced anxiety, and improved social ease.
The second pathway involves PDE4 inhibition, which regulates cyclic adenosine monophosphate (cAMP) signaling. Elevated cAMP levels in certain brain regions are linked to improved memory consolidation and reduced neuroinflammation.
Researchers are actively studying PDE4 inhibitors for memory disorders, including Alzheimer's disease, which speaks to how significant this mechanism can be. Together, these two pathways create a profile far more aligned with cognitive support than recreational intoxication.
Does Kanna Get You High? The Honest Answer Nobody Is Giving You
What People Feel: Real Reports vs. Inflated Expectations
One of the most overlooked facts about kanna is that its effects shift depending on dose. Research indicates that lower doses tend to produce stimulating, mood-lifting effects, while higher doses shift the experience toward sedation.
This means the question of whether this plant gets you high does not have a single answer. It depends heavily on how much you take and in what form.
At moderate, functional doses, which is the range relevant to a well-formulated beverage, most people report a reduction in social anxiety, a gentle lift in mood, and a sense of grounded ease. Some describe feeling more present and emotionally open without feeling out of control.
A responsible product is specifically designed to stay in the range where kanna's beneficial properties shine, well below anything that could reasonably be called intoxicating.
Why Calling Kanna "Nature's MDMA" Does More Harm Than Good
The comparison to MDMA persists because both substances influence serotonin availability. But the mechanisms and intensity differ vastly.
MDMA floods the brain with serotonin in a way that produces intense euphoria and altered perception. Kanna modulates serotonin availability more gently, closer in character to how a supportive herbal works than how a recreational drug works.
Calling kanna "nature's MDMA" is a bit like calling chamomile "nature's Valium." There is a kernel of biological logic in the comparison, but it overstates the intensity of effect and creates unrealistic expectations.
If someone comes to kanna hoping for a psychedelic experience, they are likely to be underwhelmed. If they come to it seeking genuine anxiety relief and mood support without impairment, they may find exactly what they were looking for.
Why Putting Kanna in a Can Might Be the Smartest Move in Functional Beverages
The Case for Drinking Your Botanicals
The shift toward functional beverages has created an exciting opportunity to make beneficial botanicals more accessible. For decades, kanna was primarily available as a raw powder, capsule, or extract, formats that require knowledge to use correctly.
A well-formulated ready-to-drink beverage changes that by delivering a precise, consistent dose in a familiar and enjoyable format.
This is central to what Kamello is building. By combining kanna with kava in a ready-to-drink can, Kamello creates a synergistic effect where kava contributes physical relaxation and kanna lifts mood and reduces anxiety. Kava's kavalactones and kanna's alkaloids act on entirely different receptor systems, meaning the two plants are pharmacologically complementary rather than redundant. The result is a more complete experience that neither plant could deliver alone.
Not All Kanna Is Created Equal: Why Formulation Changes Everything
Not all kanna products are equivalent, and this matters more than most labels acknowledge.
Research has shown that the concentration of active alkaloids, particularly mesembrine, varies significantly depending on whether the plant material is raw, fermented, or extracted. Fermentation, which is the traditional preparation method, appears to increase the bioavailability of key alkaloids, which is part of why indigenous communities developed that process in the first place.
This is why thoughtful formulation matters, and why Kamello's commitment to noble kava and pure kanna reflects more than just a label. When someone questions whether this herb gets you high, a significant part of the answer depends on how the plant was prepared and at what concentration it is delivered.
The Evidence That Gives Kanna Its Credibility
The Landmark Clinical Trials That Put Kanna on the Map
Several clinical trials have contributed meaningfully to the scientific case for kanna, with a few studies standing out for the specificity and rigor of their findings.
One of these is the Terburg et al. 2013 pharmaco-fMRI study, already referenced above, which demonstrated that a single 25mg dose of Zembrin measurably reduced amygdala reactivity to threatening stimuli in healthy adults. That study was notable not just for its findings but for its methodology: using functional MRI to observe real-time changes in brain activity gave it a level of objectivity that self-reported mood studies cannot match.
Another is the Chiu et al. 2014 proof-of-concept randomized controlled trial, in which 21 healthy older adults took 25mg of Zembrin daily for three weeks. Compared to placebo, participants showed statistically significant improvements in cognitive set flexibility and executive function. The authors noted that the results point toward kanna's PDE4 inhibition pathway as a promising target for early cognitive decline research.
A third study by Reay et al. 2020, published in Human Psychopharmacology, extended this picture further by testing Zembrin against laboratory-induced anxiety in healthy volunteers. Participants who took a single 25mg dose reported significantly lower subjective anxiety levels before a stress task, with measurable reductions in heart rate compared to the placebo group.
Taken together, these trials build a consistent picture of a botanical that reliably reduces anxiety and supports cognitive function at moderate doses.
Centuries of Indigenous Use: The Original Human Trial
Beyond clinical trials, kanna has centuries of documented use by the Khoikhoi and San communities of southern Africa.
Ethnobotanical records going back to the late 1600s describe consistent use of Sceletium tortuosum for mood support, social ease, and stress management. This long history of human use provides a meaningful safety context that newer synthetic compounds simply cannot offer.
It is also worth noting that the concern around combining kanna with SSRIs is a theoretical precaution based on shared serotonergic mechanisms rather than a pattern of confirmed adverse events.
No significant cases of serotonin syndrome from kanna alone have been widely reported in the clinical literature. Anyone on prescription medication should consult a healthcare provider before adding any new botanical to their routine.
Your New Ritual Is Waiting: Here Is Where to Start
So does kanna get you high? The short answer is no, not in the way most people mean. What kanna does is something arguably more valuable: it calms without sedating, elevates mood without distorting perception, and supports social ease without impairment.
Its dose-dependent nature, dual-pathway mechanism, and centuries of documented use all point to a botanical that deserves to be taken seriously on its own terms.
Kamello was built on exactly this idea. Ancient botanicals, rigorously sourced and intelligently combined, delivered in a modern format that fits your life. Whether you are winding down after work, heading into a social situation, or simply looking for a cleaner alternative to alcohol, Kamello brings the science and the ritual together in every can.
Explore what Kamello has to offer and discover your new ritual for balance and bliss.
Frequently Asked Questions
Is kanna legal in the United States?
Kanna, or Sceletium tortuosum, is not scheduled as a federally controlled substance in the United States, but that does not mean every kanna product is automatically regulated the same way.
When kanna is sold for human consumption, it is generally positioned within the dietary supplement category, which the FDA regulates under a different framework than conventional foods and drugs.
That distinction matters because dietary supplements are not FDA-approved for diagnosing, treating, curing, or preventing disease before they reach the market. The FDA explains that supplement companies are responsible for ensuring their products are safe and properly labeled, while the NIH advises consumers to be cautious because supplement evidence and quality can vary widely.
There is also an important state-level exception. Louisiana law restricts certain “prohibited plants” intended for oral or nasal use, and the state’s statute includes plant categories relevant to kanna’s botanical classification under Louisiana Revised Statutes Title 40, Section 989.2.
Because laws can differ by state and country, kanna should be treated as a locally regulated botanical rather than something that is universally legal everywhere.
Can kanna be habit-forming or addictive?
Current evidence does not suggest that kanna has the same dependence profile as substances that strongly reinforce dopamine-driven reward pathways, but it is more accurate to say that the long-term human evidence is limited.
Addiction science generally distinguishes between substances that strongly drive reward learning and compulsive use, and substances that primarily modulate mood-related neurotransmitters, as explained in the National Institute on Drug Abuse overview of addiction and the brain.
Human safety data on standardized kanna extract are encouraging but still relatively small. In a randomized, double-blind, placebo-controlled trial, researchers found that standardized Sceletium tortuosum extract was well tolerated at 8 mg and 25 mg daily for three months in healthy adults, with no major safety signals.
Preclinical research also supports a low abuse-liability signal, but animal and lab data should not be treated as proof of human outcomes. A toxicological safety assessment of a standardized kanna extract provides additional safety context in Food and Chemical Toxicology, while a broader review of kanna’s phytochemistry and pharmacology notes that more clinical research is needed before making strong long-term claims about use patterns, safety, or therapeutic potential in the Journal of Ethnopharmacology.
Does kanna show up on a drug test?
Standard workplace drug tests do not typically screen for kanna alkaloids such as mesembrine or mesembrenone. Federal workplace testing programs focus on specific authorized testing panels, and SAMHSA provides current resources for those programs through its workplace drug testing guidance.
The reason kanna is unlikely to appear on a standard test is chemical specificity. Routine tests are designed around targeted drugs and metabolites, not broad detection of every psychoactive botanical. SAMHSA’s federal testing materials explain that laboratories use defined analytes and cutoffs for workplace testing, including in its Medical Review Officer guidance manual.
The more realistic concern is product quality. The NIH notes that supplements sold online or in stores may differ from products studied in research and may carry risks related to contamination, inaccurate labeling, or interactions, as described in its guidance on dietary and herbal supplements. For that reason, third-party testing and transparent sourcing matter more than the drug-test risk of kanna itself.
Does kanna interact with antidepressants or SSRIs?
Kanna deserves caution around antidepressants because its active alkaloids appear to influence serotonin signaling. Pharmacological research has found that Sceletium tortuosum extract can inhibit the serotonin transporter and phosphodiesterase-4, mechanisms described in a peer-reviewed study on kanna’s 5-HT reuptake and PDE4 activity.
This does not mean kanna acts exactly like an SSRI, but it does mean combining it with SSRIs, SNRIs, MAOIs, MDMA, certain migraine medications, or other serotonergic agents should be approached carefully. Serotonin syndrome is a potentially serious condition caused by excessive serotonergic activity, and the clinical features are summarized in the NCBI Bookshelf review on serotonin syndrome.
There are not many well-documented human case reports showing serotonin syndrome from kanna alone, so the concern is best described as mechanistic and precautionary rather than proven as a common clinical event.
Still, because the overlap involves a meaningful neurotransmitter pathway, anyone taking antidepressants or other serotonergic medications should speak with a clinician before using kanna.
How long does it take for kanna to take effect when consumed in a beverage?
Onset can vary by product format, dose, extract type, food intake, and individual metabolism. Liquid formats may feel faster than capsules for some people because the active compounds are already dispersed in a beverage, but exact timing should be framed as variable rather than guaranteed.
Human studies on standardized kanna extracts show that measurable effects can occur under controlled conditions. In a placebo-controlled neuroimaging study, researchers found that an acute dose of standardized Sceletium tortuosum extract affected amygdala activity and amygdala-hypothalamus connectivity, which supports kanna’s relevance to stress-response pathways.
The best-supported timing claims should stay conservative because most clinical studies use standardized extracts, not every beverage format on the market. A 2021 review of Sceletium tortuosum explains that extract composition, alkaloid profile, and preparation method can influence biological activity, which is why product consistency matters.
Can kanna be used during the day without affecting productivity?
Kanna is not generally described in the research as a classic intoxicant, sedative, or hallucinogen, but daytime effects depend heavily on dose and individual response. Lower or standardized doses may feel more calming and focusing, while higher amounts may feel more relaxing or sedating for some people.
Clinical evidence suggests that standardized kanna extract may support certain cognitive measures rather than impair them. A proof-of-concept randomized controlled study found that 25 mg of Zembrin daily was associated with improvements in cognitive set flexibility and executive function in healthy adults.
Mechanistically, this may relate to kanna’s dual activity on serotonin transport and PDE4 signaling, but the evidence is still early. The human research base remains small, and the Alzheimer’s Drug Discovery Foundation notes that kanna has not been studied in large or long-term clinical trials for cognition, while summarizing the current evidence in its Cognitive Vitality review.